Flow cytometric cell cycle kinetics and quantitative measurement of c- erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies

Clinical Biochemistry

Volumn 30, Issue 3, 1997, Pages 209-214

  Eissa, Sanaa ^a   Saada, Maged Abu ^a   El Sharkawy, Tarek ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

benign endometrial lesions; oncegenes; tumor suppressor genes

Indexed keywords

DNA; MUTANT PROTEIN; PROTEIN P53;

ADULT; ANEUPLOIDY; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOLOGY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; BIOPSY; CELL CYCLE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030978981     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(96)00171-3     Document Type: Article

References (33)

1. Kurman RJ, Karrinski PF, Norris HJ. The behavior of endometrial hyperplasia. A long term study of untreated hyperplasia in 170 patients. Cancer 1985; 56: 403-7.
2. White LN. An overview of screening and early detection of gynecologic malignancies. Cancer 1993; 71: 1400-5.
3. Bibbo M, Dytch HE, Alenghat E, et al. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989; 92: 261-5.
4. Newton JA, Camplejohn RS, McGibbon DH. Aneuploidy in Bowen's disease. Br J Dermatol 1986; 114: 691-4.
5. Reid JB, Haggitt RC, Rubin CE, et al. Barrett's esophagus: Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93: 1-11.
6. Ono J, Auer G. The significance of DNA measurements for the early detection of bronchial cell atypia. Cytometry 1983; 3: 340-4.
7. Harris CC, Hollstein M. The clinical implications of p53 tumor suppressor gene. N Engl J Med 1993; 28: 380-3.
8. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991; 164: 15-19.
9. Press M. HER-2/neu gene amplification and expression in human carcinomas: Implications for clinical management. Abstracts of the 2nd International Cancer Molecular Biology Symposium, Cairo, Egypt 1993: 96.
10. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Bioch. 1976; 72: 248-51.
11. Thornton JG, Quirke P, Wells M. Flow cytometry of normal, hyperplastic and malignant human endometrium. Am J Obstet Gynecol 1989; 161: 487-91.
12. Izumi S, Yamaoka K, Aria H, et al. Flow cytometric DNA analysis of uterine endometrial carcinoma. Nippon Sanka Fujinka Gakkai Zasshi 1991; 43(7): 722-8.
13. Feichter GE, Hoffken H, Keep J. DNA now cytometric measurements on the normal, atrophic, neoplastic human endometrium. Virchows Arch 1982; 398: 53-6.
14. Tase T, Toki T, Dikawa N, Wada Y, Yajima A, Suzuki M. Flow cytometric DNA analysis of human endometrial carcinoma. Tohoku J Exp Med 1985; 146(4): 429-37.
15. Tsou K, Hong D, Varello MA, et al. Flow cytometric DNA and 5′-nucleotide phosphodiesterase in endometrium. Cancer 1985; 56: 2340-7.
16. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, Transforming growth factor alpha, Epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Human Pathol 1994; 25: 1075-83.
17. Jiko K, Sasano H, Ito K, Ozawa N, Sato Sh, Yajima A. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993; 13: 305-10.
18. Koshiyama M, Konishi I, Wang DP, et al. Immunohistochemical analysis of p53 protein over expression in endometrial carcinomas: Inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histopathol 1993; 423(4): 265-71.
19. Kohler MF, Berchuck A, Davidoff AM, et al. Over expression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622-7.
20. Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 over expression in endometrial cancers. Int J Cancer 1994; 58(1): 14-19.
21. Ito K, Nasim S, Sasano H, Yajima A, Garrett CT. Prognostic significance of p53 overexpression and k-ras mutation in endometrial cancer. Proc Ann Meet Am Asso Cancer Res 1994; 35: A1208.
22. Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994; 73(6): 1686-92.
23. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, p53, PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53(1): 84-92.
24. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994; 73(9): 2380-5.
25. Massenkeil G, Caduff R, Oberhuber H, et al. Loss of heterozygosity on chromosome 16q, expression of HER2/neu and p53 mutations in endometrial cancer. Int J Oncol 1995; 6(1): 157-62.
26. Sato S, Ito K, Ozawa N, Yajima A, Sasano H. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. Exp Med 1991; 165(2): 137-41.
27. Brumm C, Riviere A, Wilckens C, Loning T. Immunohistochemical investigation and northern blot of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. Virchows Arch A Pathol Analyt Histopathol 1990; 417(6): 477-81.
28. Tandon AK, Clark GM, Chanmess G, Ullrich A, Mc Guire W. HER-2/neu oncogene protein and prognosis in breast cancer. Clin Oncol 1989; 7: 1120-8.
29. Carny WP, Hamer PJ, Petit D, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 1991; 6: 53.
30. Sampson E, Teramoto Y. Quantitation of c-erbB-2 oncoprotein in human breast tissue. In: Current Tumor Diagnosis: Applications, Clinical Relevance, Research, Trends. Ed. Klapdor R, Pp. 510-14. Munch, Bern, Wien, New York: Zuckschwerdt Verlag, 1994.
31. Zeheb R, McComack S, Sofensen C, Reynoids F, Sorvillo JM. Quantitation of mutant p53 in mammalian cell extracts. Reproduction of poster presented at the 5th Annual p53 Workshop, Princeton University, NJ 1993.
32. Diamandis EP, Levesque MA. Assessment of p53 overexpression by non-immunohistochemical methods. J Pathol 1995; 175: 93-5.
33. Lavine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.